Credit: University of Surrey A study published in Research in Veterinary Science demonstrates that vitamin D supplementation can reduce the severity of tuberculosis (TB) in wild boar and red deer Wild boar and red deer are key hosts of TB and transmit the disease to cattle and other species, causing a major problem in farm and domestic animals across Europe Nutritional supplementation could be used as a novel control measure Innovative pilot study was carried out in Spain by the Universities of Surrey and Extremadura, and animal conservation company Ingulados Wild boar and red deer are key hosts of bovine tuberculosis – a chronic, infectious disease mainly caused by Mycobacterium bovis - in southern Europe, with the incidence of TB in these animals particularly high in certain areas of Spain. The research could therefore have a positive impact on animal health and – since these species are valuable in the hunting and meat products industries – local economies.
The research also concludes that vitamin D supplementation could be explored in other species such as badgers, which are key hosts for bovine tuberculosis in the UK. Vitamin D – and other nutritional factors – are known to influence the severity of TB in humans but its relationship with cattle and other mammals has not been studied until now. The research takes an innovative 'One Health' approach, which explores human and animal health in a holistic way using key learnings across both disciplines. At the University of Surrey, expert in human nutrition Professor Susan Lanham-New collaborated closely with veterinary scientists from the University's School of Veterinary Medicine. In the pilot study, half of the animals were given a vitamin D3-enriched food while half were given no supplementation. Among animals with TB, there was a clear correlation between the severity of the disease and their blood concentration of vitamin D3. These animals were also more likely to be suffering from a localised TB infection than severe generalised TB.
Dr F. Javier Salguero of the University of Surrey said, "We know that eradicating TB – a massive problem in animals worldwide – is a complicated process. However, nutritional factors could play a significant role as a preventative measure. This research points to the fact that supplementing animals' diet with vitamin D could be a very cost effective approach to reduce prevalences." The researchers are now planning to test vitamin D supplementation in wild boar and red deer on a larger scale in Spain, as well as exploring how vitamin D improves immunity against TB in these animals. Certain factors affect vitamin D levels in children with chronic kidney disease The FastPack® IP System is the only quantitative immunoassay analyzer available which features one-touch operation in delivering values for Vitamin D, Thyroid Stimulating Hormone (TSH), Free Thyroxine (fT4), Prostate Specific Antigen (PSA), Testosterone and Human Chorionic Gonadotropin (hCG). The system is simple, compact and provides lab quality performance in a matter of minutes.
The ability to provide "Just in Time" test results will prove to be critical when quick answers can make the difference in the development of a diagnosis or treatment protocol. You will quickly find that the FastPack® IP System will easily become a crucial part of any successful laboratory. FastPack® IP Vitamin D Immunoassay Vitamin D, known as the sunshine vitamin, is part of a group of fat‑soluble prohormones which encourage the metabolism of calcium and phosphorus in the body. Increasing research is now uncovering evidence illustrating the importance of vitamin D in the protection against a whole host of health issues. It is also estimated that as much as half the population in the world is deficient in vitamin D. Qualigen, Inc. is excited to announce the development of its newest addition to the FastPack® IP family of rapid immunoassays, FastPack® IP Vitamin D. The FastPack® IP Vitamin D immunoassay is intended for the quantitative determination of total 25‐hydroxyvitamin D and other hydroxylated metabolites in human serum and plasma.
This assay is designed for use with the FastPack® IP System which is designed specifically for use in the practice laboratory setting. FastPack® IP TSH Immunoassay Realizing the importance of the thyroid hormones involved in regulating many of the systems found in the body, it becomes essential to have the ability to conveniently measure these values. The FastPack® IP TSH immunoassay is a chemiluminescent immunoassay for the in-vitro quantitative determination of thyroid stimulating hormone (TSH) in human serum and plasma. Measurements of TSH produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders. The FastPack® IP TSH immunoassay is designed for use with the FastPack® IP System and will provide these important quantitative test values. FastPack® Control – United States FastPack® Control - International FastPack® IP Free T4 Immunoassay In addition to thyroid stimulating hormone, Qualigen has made available the FastPack® IP Free T4 immunoassay.
Determining Free T4 levels in the blood is essential in estimating the actual amount of T4 flowing in the blood and ultimately estimating the function of the thyroid gland. FastPack® IP Free T4 is a chemiluminescent immunoassay for the in-vitro quantitative determination of free thyroxin (fT4) in human serum. The FastPack® IP Free T4 immunoassay is designed for use with the FastPack® IP System. FastPack® IP Total PSA The ability to test for Prostate Specific Antigen (PSA) has revolutionized the diagnosis and management of prostate disease. It is highly recognized that PSA testing plays a fundamental role in the early detection and monitoring of prostate disease, which many times will dictate the manner in which patients are treated. FastPack® IP Total PSA makes this test available to you at your fingertips. The FastPack® IP Total PSA immunoassay is a chemiluminescent immunoassay for the in-vitro quantitative determination of PSA in human serum and plasma as an aid in the management of patients with prostate cancer.
The FastPack® IP Total PSA immunoassay is designed for use with the FastPack® IP System. Direction Insert Direction Insert - EU Only Calibrators Calibrators - EU Only FastPack® IP Testo Immunoassay Testosterone is a steroid hormone present in mammals that is primarily produced by the testes in males and the ovaries in females. The determination of testosterone levels in the body is crucial in the assessment of hypogonadal states, tumor detection and in monitoring hormone replacement. The FastPack® IP Testo Immunoassay is a chemiluminescent immunoassay for the in-vitro quantitative determination of total testosterone in human serum and plasma. The FastPack® IP Testo Immunoassay is designed for use with the FastPack® IP System. FastPack® IP hCG Immunoassay The rapid rise in the production of Human Chorionic Gonadotropin (hCG) during the first trimester of a normal human pregnancy has made hCG a dependable indicator of the presence or absence of an implanted embryo.
In addition to pregnancy testing, the ability to quantitate levels of hCG is useful in the evaluation of ectopic pregnancies and in monitoring germ cell and trophoblastic tumors. The FastPack® IP hCG Immunoassay is a chemiluminescence assay based on the "sandwich" principle which provides a quantitative value in measuring the level of hCG in human serum or plasma. The FastPack® IP hCG Immunoassay is designed for use with the FastPack® IP System. FastPack® IP Free PSA Immunoassay FastPack® IP Free PSA immunoassay is a chemiluminescent immunoassay for the in-vitro quantitative determination of free prostate-specific antigen (free PSA) in human serum. FastPack® IP Free PSA immunoassay is designed for use in conjunction with the FastPack® IP System for calculating the ratio of free/total PSA, expressed as a percentage (percent free PSA). The percent free PSA, as measured by the FastPack® IP System, is intended for use as an aid to differentiate between prostate cancer and benign prostatic conditions.
FastPack® IP GST Immunoassay It is found that the detection of GST subclass levels in biological fluids would be of significant use in monitoring the integrity of specific hepatic regions in the liver. Since αGST has been found to be equally distributed in both the centrilobular and periportal regions of the liver, αGST would be a more sensitive indicator of hepatic status in a variety of clinical conditions including Allograft Rejection, Viral Hepatitis, Chronic Active Hepatitis and Hepatotoxicity. The FastPack® IP αGST Immunoassay is for the in-vitro quantitative determination of αGST in human serum and plasma. Measurement of αGST can be used as an aid in the assessment of liver damage. The FastPack® IP αGST Immunoassay is designed for use with the FastPack® IP System. FastPack® IP GST Immunoassay (Research Use Only) It is found that the detection of GST subclass levels in biological fluids would be of significant use in monitoring the integrity of specific hepatic regions in the liver.